Reprogram Biosciences is a preclinical oncology biotechnology company. Founded in 2025, the company develops mRNA-based therapeutics that reprogram tumor cells to activate the immune system, with a focus on treating solid tumors with high unmet need. Reprogram's CellRecodeX discovery platform uses biological foundation models to accelerate candidate identification and support pipeline expansion.

Key Contact